Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Reno, NV
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Reno, NV
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Bronx, NY
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Stony Brook, NY
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Stony Brook, NY
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Cincinnati, OH
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Columbus, OH
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Tulsa, OK
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Kittanning, PA
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Kittanning, PA
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Willow Grove, PA
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Willow Grove, PA
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Columbia, SC
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Columbia, SC
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Knoxville, TN
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Memphis, TN
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
The Woodlands, TX
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
The Woodlands, TX
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Abingdon, VA
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Abingdon, VA
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Richmond, VA
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Tacoma, WA
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Tacoma, WA
Click here to add this to my saved trials
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Milwaukee, WI
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Sirolimus and Cetuximab in Advanced Malignancies
A Phase I Trial of Sirolimus and Cetuximab in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Sirolimus and Cetuximab in Advanced Malignancies
A Phase I Trial of Sirolimus and Cetuximab in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Bevacizumab With/Without Cetuximab by K-RAS Mutational Status and Liver Function for Advanced Cancers Metastatic to the Liver
Status: Enrolling
Updated:  11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab
Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Bevacizumab With/Without Cetuximab by K-RAS Mutational Status and Liver Function for Advanced Cancers Metastatic to the Liver
Status: Enrolling
Updated: 11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
HAI Abraxane With Gemcitabine and Bevacizumab
A Phase I Study of Hepatic Arterial Infusion (HAI) of Abraxane in Combination With Gemcitabine and Bevacizumab for Patients With Advanced Cancers Metastatic to the Liver
Status: Enrolling
Updated:  11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
HAI Abraxane With Gemcitabine and Bevacizumab
A Phase I Study of Hepatic Arterial Infusion (HAI) of Abraxane in Combination With Gemcitabine and Bevacizumab for Patients With Advanced Cancers Metastatic to the Liver
Status: Enrolling
Updated: 11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Aurora, CO
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Houston, TX
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
San Antonio, TX
Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies
Open Label, Phase I Study to Determine the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Biomarker Status of BAY73-4506 in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
Phase I Trial of Sunitinib Plus Temsirolimus in Patients With Metastatic Renal Cell Cancer
Status: Enrolling
Updated:  11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
Phase I Trial of Sunitinib Plus Temsirolimus in Patients With Metastatic Renal Cell Cancer
Status: Enrolling
Updated: 11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
B-Receptor Signaling in Cardiomyopathy
B-Receptor Signaling in Cardiomyopathy
Status: Enrolling
Updated:  11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
B-Receptor Signaling in Cardiomyopathy
B-Receptor Signaling in Cardiomyopathy
Status: Enrolling
Updated: 11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Bendamustine and Bevacizumab for Advanced Cancers
A Phase I Study of Bendamustine and Bevacizumab for Patients With Advanced Cancers
Status: Enrolling
Updated:  11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Bendamustine and Bevacizumab for Advanced Cancers
A Phase I Study of Bendamustine and Bevacizumab for Patients With Advanced Cancers
Status: Enrolling
Updated: 11/16/2015
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Trientine and Carboplatin in Advanced Malignancies
Phase I Study of Trientine and Carboplatin in Patients With Advanced Malignancies
Status: Enrolling
Updated:  11/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Trientine and Carboplatin in Advanced Malignancies
Phase I Study of Trientine and Carboplatin in Patients With Advanced Malignancies
Status: Enrolling
Updated: 11/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Tucson, AZ
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Fort Myers, FL
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Fort Myers, FL
Click here to add this to my saved trials
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
St. Petersburg, FL
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Chapell Hill, NC
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Chapell Hill, NC
Click here to add this to my saved trials
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Cincinnati, OH
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Toledo, OH
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Toledo, OH
Click here to add this to my saved trials
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/16/2015
Clinical Research Facility
mi
from
Nashville, TN
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/16/2015
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated:  11/16/2015
Investigational Site
mi
from
Brussels,
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
An Open-Label, Multicenter, Randomized, Phase Ib/II Study of E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Patients With Hepatocellular Carcinoma
Status: Enrolling
Updated: 11/16/2015
Investigational Site
mi
from
Brussels,
Click here to add this to my saved trials
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Status: Enrolling
Updated:  11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
Status: Enrolling
Updated: 11/16/2015
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Imaging Study Compare 4DCT Image
An Imaging Study to Compare Methods to Reduce 4DCT Image Acquisition Artifacts
Status: Enrolling
Updated:  11/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Imaging Study Compare 4DCT Image
An Imaging Study to Compare Methods to Reduce 4DCT Image Acquisition Artifacts
Status: Enrolling
Updated: 11/16/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Status: Enrolling
Updated:  11/16/2015
NYU Hospital for Joint Diseases
mi
from
New York, NY
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Pilot Study: Cardiovascular Events in High Risk Orthopedic Surgical Patients
Status: Enrolling
Updated: 11/16/2015
NYU Hospital for Joint Diseases
mi
from
New York, NY
Click here to add this to my saved trials
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Phase II Study to Investigate Concurrent Lapatinib and Radiotherapy in Locally Advanced or Locally Recurrent Breast Cancer and the Impact on Breast Cancer Stem Cells
Status: Enrolling
Updated:  11/16/2015
Stanford University Cancer Institute
mi
from
Stanford, CA
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Phase II Study to Investigate Concurrent Lapatinib and Radiotherapy in Locally Advanced or Locally Recurrent Breast Cancer and the Impact on Breast Cancer Stem Cells
Status: Enrolling
Updated: 11/16/2015
Stanford University Cancer Institute
mi
from
Stanford, CA
Click here to add this to my saved trials
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Veterans Affairs Outpatient Clinic - Martinez
mi
from
Martinez, CA
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Veterans Affairs Outpatient Clinic - Martinez
mi
from
Martinez, CA
Click here to add this to my saved trials
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
University of California, Davis Medical Center
mi
from
Sacramento, CA
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
University of California, Davis Medical Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
CCOP - Central Illinois
mi
from
Decatur, IL
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
CCOP - Central Illinois
mi
from
Decatur, IL
Click here to add this to my saved trials
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
CCOP - Wichita
mi
from
Wichita, KA
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
CCOP - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
Veterans Affairs Medical Center - Wichita
mi
from
Wichita, KA
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
Veterans Affairs Medical Center - Wichita
mi
from
Wichita, KA
Click here to add this to my saved trials
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
CCOP - Kansas City
mi
from
Kansas City, MO
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
CCOP - Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated:  11/16/2015
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
A Phase II Trial of R115777 (NSC #702818) in Patients With Advanced Pancreas Cancer
Status: Enrolling
Updated: 11/16/2015
CCOP - Montana Cancer Consortium
mi
from
Billings, MT
Click here to add this to my saved trials